Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
News
Vacancy: Postdoctoral Researcher – Myeloid Leukaemia
24 March 2025
Melanoma progression driven in part by fatty acid uptake
28 February 2025
Biomedical Research Career Week back for another year
25 February 2025
Publications
-
Self-interactive learning: Fusion and evolution of multi-scale histomorphology features for molecular traits prediction in computational pathology
Hu Y. et al, (2025), Medical Image Analysis, 101, 103437 - 103437
-
Isorhamnetin exerts anti-proliferative effect on cancer-associated fibroblasts by inducing cell cycle arrest
Ganbold M. et al, (2025), Biomedicine & Pharmacotherapy, 185, 117954 - 117954
-
HIF2α: the interface between oxygen-sensing systems in physiology and pathology
Bishop T. and Ratcliffe PJ., (2025), Physiology
Seminars
Ludwig Oxford EpiCancer 2025
The Ludwig Oxford EpiCancer Symposium will be held on the 26 and 27th June 2025.
Read more
